These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Parathyroid scintigraphy: first experiences with technetium (III)-99m-Q12.
    Author: Aigner RM, Fueger GF, Wolf G.
    Journal: Eur J Nucl Med; 1997 Mar; 24(3):326-9. PubMed ID: 9143473.
    Abstract:
    We report the preliminary results of a prospective study demonstrating technetium(III)-99m furifosmin (Q12) uptake in histologically proven parathyroid adenomas. Scintigraphy was performed in 12 patients with hyperparathyroidism. Q12 correctly identified the parathyroid adenomas by focal prolonged tracer retention in ten of the 12 patients. In the two patients without localized tracer retention, no parathyroid adenoma could be identified surgically, either. The retention half-times ranged from 0.5 to 1.8 h (mean 1.27) in the parathyroid adenomas and from 0.3 to 1.2 h (mean 1.05) in the thyroid gland. Our preliminary results show that Q12 is a feasible, sensitive tracer for parathyroid scintigraphy. In comparison to sestamibi (MIBI) and tetrofosmin, Q12 displays short retention in the thyroid gland, which would seem rather advantageous. Further evaluation is needed to determine which among Q12, tetrofosmin and MIBI is most sensitive for the detection especially of small parathyroid adenomas, and which tracer properties will best reflect the degree of endocrine activity.
    [Abstract] [Full Text] [Related] [New Search]